1.09
Lucid Diagnostics Inc stock is traded at $1.09, with a volume of 274.73K.
It is down -1.80% in the last 24 hours and up +1.87% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.11
Open:
$1.12
24h Volume:
274.73K
Relative Volume:
0.32
Market Cap:
$142.90M
Revenue:
$4.35M
Net Income/Loss:
$-45.53M
P/E Ratio:
-1.0093
EPS:
-1.08
Net Cash Flow:
$-44.79M
1W Performance:
-2.68%
1M Performance:
+1.87%
6M Performance:
-8.40%
1Y Performance:
+42.11%
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
LUCD
Lucid Diagnostics Inc
|
1.09 | 145.52M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
124.84 | 217.03B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.06 | 142.51B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.22 | 135.66B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.52 | 124.70B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.85 | 50.07B | 5.88B | 1.34B | 799.60M | 2.3489 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Ideas Watch: Will Lucid Diagnostics Inc stock see PE expansionWeekly Investment Summary & AI Driven Stock Price Forecasts - moha.gov.vn
Bull Run: Why Lucid Diagnostics Inc stock remains on buy listsJuly 2025 Gainers & Community Verified Trade Signals - moha.gov.vn
Here’s Why Lucid Diagnostics (LUCD) Declined in Q3 - Insider Monkey
Here's Why Lucid Diagnostics (LUCD) Declined in Q3 - Finviz
Lucid Diagnostics files for $175 mln mixed securities shelf offering - MSN
Can Lucid Diagnostics Inc. stock reach $100 price targetJuly 2025 Momentum & Comprehensive Market Scan Reports - Улправда
What valuation multiples suggest for Lucid Diagnostics Inc. stockJuly 2025 WrapUp & Smart Allocation Stock Tips - DonanımHaber
Can Lucid Diagnostics Inc. stock rebound after recent weakness2025 Trade Ideas & Free Safe Capital Growth Stock Tips - DonanımHaber
How analysts rate Lucid Diagnostics Inc. stock todayInflation Watch & Consistent Return Strategy Ideas - DonanımHaber
Brokerages Set Lucid Diagnostics Inc. (NASDAQ:LUCD) Price Target at $3.94 - Defense World
Lucid Diagnostics Earnings Notes - Trefis
Can Lucid Diagnostics Inc stock rebound after recent weakness2025 Top Decliners & Verified Momentum Stock Ideas - moha.gov.vn
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt? - simplywall.st
Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price - Defense World
Lucid Diagnostics Stock (LUCD) Opinions on Recent Clinical Data Release - Quiver Quantitative
Lucid Diagnostics (NASDAQ:LUCD) Given New $8.25 Price Target at Ascendiant Capital Markets - MarketBeat
LUCD FinancialsIncome Statement - Quiver Quantitative
Ascendiant Capital Maintains Lucid Diagnostics (LUCD) Buy Recommendation - Nasdaq
Lucid Diagnostics stock price target raised to $8.25 at Ascendiant Capital By Investing.com - Investing.com South Africa
Lucid Diagnostics stock price target raised to $8.25 at Ascendiant Capital - Investing.com Canada
Lucid Diagnostics files $175M mixed securities shelf - MSN
Lucid Diagnostics reports real-world data on esophageal test device By Investing.com - Investing.com Australia
Lucid Diagnostics (LUCD) Stock: Surge After Real-World EsoGuard Data Breakthrough! - parameter.io
Lucid Diagnostics reports real-world data on esophageal test device - Investing.com
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection - PR Newswire
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus
A Look at Lucid Diagnostics Inc (LUCD) Shares in the Recent Past Indicates Growth - Setenews
Should I hold or sell Lucid Diagnostics Inc. stock in 2025Weekly Market Outlook & Weekly High Return Stock Opportunities - Newser
Why Lucid Diagnostics Inc. stock appeals to analysts2025 Retail Activity & Safe Investment Capital Preservation Plans - Newser
Lucid Diagnostics (LUCD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lucid Diagnostics stock falls after pricing capital raise of $15M via stock offering - MSN
Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% - Yahoo Finance
Is Lucid Diagnostics Inc (LUCD) positioned for future growth? - Setenews
Why Being Public Gave PavMed a Competitive Edge - Medical Device and Diagnostic industry
Get in on Lucid Diagnostics Inc’s (LUCD) buy-in window today! - Setenews
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree - PR Newswire
Ranking Lucid Diagnostics Inc. among high performing stocks via tools2025 Top Decliners & AI Powered Trade Plan Recommendations - newser.com
Lucid Diagnostics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Developing predictive dashboards with Lucid Diagnostics Inc. dataBear Alert & Fast Gain Swing Alerts - newser.com
Lucid Diagnostics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Live market analysis of Lucid Diagnostics Inc.Weekly Market Report & Long Hold Capital Preservation Tips - newser.com
Why retail investors favor Lucid Diagnostics Inc. stockAnalyst Downgrade & Stock Portfolio Risk Control - newser.com
Is Lucid Diagnostics Inc. stock oversold or undervaluedMarket Growth Report & Pattern Based Trade Signal System - newser.com
Measuring Lucid Diagnostics Inc.’s beta against major indices - newser.com
Pavmed Inc. Reports Q3 2025 Earnings and Strategic Focus - TipRanks
Lucid Diagnostics’ Earnings Call: Strategic Wins Amid Challenges - MSN
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
May 20 '25 |
Buy |
1.29 |
187,098 |
242,292 |
187,098 |
| Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
| Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):